Valuation: AnaptysBio, Inc.

Market Cap 1.72B 1.51B 1.39B 1.28B 2.41B 166B 2.45B 16.64B 6.52B 81.03B 6.45B 6.31B 279B P/E 2026 *
-203x
P/E 2027 * 12.7x
Enterprise Value 1.63B 1.42B 1.32B 1.21B 2.28B 157B 2.32B 15.74B 6.17B 76.67B 6.1B 5.97B 264B EV / Sales 2026 *
17.2x
EV / Sales 2027 * 9.3x
Free-Float
94.32%
Yield 2026 *
-
Yield 2027 * -
1 day-13.29%
1 week-24.25%
Current month-25.50%
1 month-12.55%
3 months-25.51%
6 months+10.09%
Current year+3.73%
1 week 50.24
Extreme 50.24
70.91
1 month 50.24
Extreme 50.24
70.91
Current year 42
Extreme 42
73.3
1 year 17.11
Extreme 17.1062
73.3
3 years 12.21
Extreme 12.21
73.3
5 years 12.21
Extreme 12.21
73.3
10 years 10
Extreme 10
134
Manager TitleAgeSince
Chief Executive Officer 46 2022-03-20
Director of Finance/CFO 42 2026-05-10
Corporate Officer/Principal 35 2021-12-31
Director TitleAgeSince
Director/Board Member 79 2015-06-29
Director/Board Member 63 2015-06-29
Director/Board Member 49 2021-04-07
Date Insider Type Main position Quantity % Market Cap.
6/15/26 Fiscal year

Director

12,060 0.0414%
6/15/26 Fiscal year

Chairman

12,060 0.0414%
6/15/26 Fiscal year

Director

12,060 0.0414%
Change 5-day change 1-year change 3-year change Capi.($)
-13.29%-24.25%+94.02%+164.68% 1.72B
+0.21%-1.34%+53.17%+60.65% 53.83B
+5.37%+0.75%+50.39%+83.03% 52.1B
-1.20%-7.43%+4.35%+406.96% 23.48B
+0.74%+0.73%-16.23%-15.55% 23.13B
+3.46%+0.79%+34.01%-4.47% 19.36B
-1.18%-1.15%+30.12%-32.02% 17.56B
-1.67%-8.56%+163.95%+284.69% 15.2B
+3.62%-2.42%+29.70%+663.64% 14.83B
-0.70%-1.72%+24.87%+184.19% 14.06B
Average -0.46%-3.46%+46.83%+179.58% 23.53B
Weighted average by Cap. +1.37%-2.42%+41.85%+141.02%

Financials

2026 *2027 *
Net sales 94.28M 82.63M 76.38M 70.25M 133M 9.09B 135M 913M 358M 4.45B 354M 346M 15.33B 153M 134M 124M 114M 215M 14.77B 219M 1.48B 582M 7.23B 575M 563M 24.9B
Net income -7.47M -6.55M -6.05M -5.56M -10.5M -720M -10.67M -72.34M -28.36M -352M -28.04M -27.43M -1.21B 129M 113M 104M 95.91M 181M 12.41B 184M 1.25B 489M 6.07B 483M 473M 20.92B
Net Debt -92.22M -80.83M -74.72M -68.72M -130M -8.89B -132M -893M -350M -4.35B -346M -339M -14.99B -293M -257M -237M -218M -412M -28.26B -419M -2.84B -1.11B -13.83B -1.1B -1.08B -47.64B
Logo AnaptysBio, Inc.
AnaptysBio, Inc. is a royalty management company. The Company manages the financial collaborations for Jemperli with GlaxoSmithKline (GSK) and imsidolimab with Vanda Pharmaceuticals Inc. (Vanda). The Company's financial collaboration with GSK is focused upon the development and commercialization of Anaptys-discovered Jemperli (dostarlimab), a PD-1 antagonist, approved for endometrial cancer and dMMR pan tumors, and is being studied in rectal cancer, colon cancer and head and neck squamous cell carcinoma. The Company's financial collaboration with Vanda is focused upon the development and commercialization of Anaptys-discovered imsidolimab, an IL-36R antagonist, which is being developed for generalized pustular psoriasis (GPP).
Employees
104
Date Price Change Volume
26-07-20 US$50.29 -13.29% 1,221,763
26-07-17 US$58.00 +7.11% 732,652
26-07-16 US$54.15 -2.99% 866,367
26-07-15 US$55.82 -10.70% 1,546,208
26-07-14 US$62.51 -10.46% 623,074
Trader
Investor
Global
Quality
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
50.29USD
Average target price
87.09USD
Spread / Average Target
+73.18%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ANAB Stock